NasdaqGM - Nasdaq Real Time Price USD

Alvotech (ALVO)

10.51

+0.01

+(0.10%)

As of 2:29:41 PM EDT. Market Open.

There May Be Underlying Issues With The Quality Of Alvotech's (NASDAQ:ALVO) Earnings

Alvotech ( NASDAQ:ALVO ) just reported some strong earnings, and the market reacted accordingly with a healthy uplift...

Simply Wall St. 7 hours ago

ALVO
+0.10%

ALVOW
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report

It's been a pretty great week for Alvotech ( NASDAQ:ALVO ) shareholders, with its shares surging 18% to US$9.68 in the...

Simply Wall St. 5 days ago

ALVO
+0.10%

ALVOW
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2

GlobeNewswire 6 days ago

ALVO
+0.10%

ALVOW
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 8, 2025) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wor

GlobeNewswire 7 days ago

ALVO
+0.10%

ALVOW
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $2

GlobeNewswire 7 days ago

ALVO
+0.10%

ALVOW
Exploring High Growth Tech Stocks In The US Market

In the current landscape of the United States market, investors are closely monitoring mixed stock performances as they await key announcements such as the Federal Reserve's interest rate decision and developments in trade negotiations with China. Amid this backdrop, high growth tech stocks continue to capture attention for their potential to thrive despite economic uncertainties, making them a focal point for those seeking opportunities in an evolving market environment.

Simply Wall St. 8 days ago

AGYS

ALVO
+0.10%

ALVOW
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company’s product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currentl

GlobeNewswire 8 days ago

ALVO
+0.10%

ALVOW
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025SELARSDI is approved for all indications matching the reference productSELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to seve

GlobeNewswire 10 days ago

TEVA

TEVJF

ALVO
+0.10%
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio o

GlobeNewswire 13 days ago

ALVO
+0.10%

ALVOW
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at

GlobeNewswire 13 days ago

ALVO
+0.10%

ALVOW
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a mediocre week for Alvotech ( NASDAQ:ALVO ) shareholders, with the stock dropping 17% to US$9.55 in the week...

Simply Wall St. last month

ALVO
+0.10%

ALVOW
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Alvotech ( NASDAQ:ALVO ) Full Year 2024 Results Key Financial Results Revenue: US$492.0m (up 427% from FY 2023). Net...

Simply Wall St. last month

ALVO
+0.10%

ALVOW
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a d

GlobeNewswire last month

ALVO
+0.10%

ALVOW
Alvotech Reports Record Results for 2024 and Provides Business Update

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a business update conference call a

GlobeNewswire last month

ALVO
+0.10%

ALVOW
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announ

GlobeNewswire last month

ALVO
+0.10%

ALVOW
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane’s

GlobeNewswire last month

ALVO
+0.10%

ALVOW
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India & REYKJAVIK, Iceland, March 18, 2025--Alvotech and Dr. Reddy’s announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.

Business Wire last month

ALVO
+0.10%

ALVOW

RDY
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has dropped 3.7%, yet it remains up by 6.9% over the past year with earnings forecasted to grow by 14% annually. In this context of fluctuating performance, identifying high growth tech stocks that can potentially capitalize on these trends involves looking for companies with strong innovation capabilities and robust financial health.

Simply Wall St. 2 months ago

MAX

BTBT

ALVO
+0.10%
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of the management team will host one-on-one meetings. Alvotech will also be participating in a fir

GlobeNewswire 2 months ago

ALVO
+0.10%

ALVOW
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the full year 2024, after U.S. markets close on Wednesday, March 26, 2024. Following the release, Alvotech will conduct a conference call for analysts on Thursday, March 27, 2025, at 8:00 am ET (12 noon GMT). Live audio of the conference call will be webcast and available to members of the news

GlobeNewswire 2 months ago

ALVO
+0.10%

ALVOW

Performance Overview

Return	ALVO	S&P 500 (^GSPC)
YTD	-20.56%	+0.59%
1-Year	-21.27%	+11.46%
3-Year	+10.63%	+47.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alvotech (ALVO)

There May Be Underlying Issues With The Quality Of Alvotech's (NASDAQ:ALVO) Earnings

Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report

Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

Exploring High Growth Tech Stocks In The US Market

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets

Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech Reports Record Results for 2024 and Provides Business Update

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Exploring 3 High Growth Tech Stocks In The US Market

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Performance Overview